Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2062MR)

This product GTTS-WQ2062MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2062MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12401MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ7103MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ10077MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ477MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ11390MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ3260MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ14971MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ388MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW